LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Blood Gas Analyzers Market to Surpass USD 940 Million by 2026

By LabMedica International staff writers
Posted on 22 Jun 2019
Print article
The global blood gas analyzers market was valued at USD 594.6 million in 2017 and is projected to grow at a CAGR of 5.5% over the forecast period (2018 – 2026) to surpass USD 940 million by 2026. The market growth is expected to be driven by the increasing global geriatric population across that is highly susceptible to various chronic diseases, aided further by increasing patients being treated in ICUs and emergency departments.

These are the latest findings of Coherent Market Insights (Seattle, WA, USA), a market research and consulting firm.

However, the high possibility of infections transmitted through blood gas analyzers that are affected by patient-acquired infections such as blood-borne pathogens during testing procedures is likely to hamper the market growth. Additionally, blood gas analyzers are difficult to use and require trained personnel. Moreover, the collection of arterial blood is more difficult than venous or capillary blood sample and can be more painful to the patient or even dangerous in case incorrect procedure is followed. All these factors are expected to negatively impact the growth of the global blood gas analyzers market.

The market players are focusing on developing cost-effective, easy-to-use blood gas analyzers that deliver reliable and fast results. They are also focusing on developing portable blood gas analyzers in order to increase the usability and comfort of the devices.

Geographically, the North American blood gas analyzers market is expected to generate significant revenue during the forecast period, driven by the rising lifestyle-induced diseases and high emergency department visits. The blood gas analyzers market in Asia-Pacific is expected to register the highest growth during the forecast period due to the region’s increasing patient population.

Related Links:
Coherent Market Insights

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more